Brief: Enlivex Doses First Patient In Placebo-Controlled Phase IIb Trial Testing Allocetra In Critical COVID-19 Patients With ARDS
22/09/2021 11:13
Sept 22 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX DOSES FIRST PATIENT IN PLACEBO-CONTROLLED PHASE
IIB
CLINICAL TRIAL EVALUATING ALLOCETRA IN SEVERE AND CRITICAL
COVID-19 PATIENTS WITH ARDS
Source text for Eikon: ID:nGNX8L5y5J
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment